0001209191-21-068113.txt : 20211206 0001209191-21-068113.hdr.sgml : 20211206 20211206164714 ACCESSION NUMBER: 0001209191-21-068113 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211123 FILED AS OF DATE: 20211206 DATE AS OF CHANGE: 20211206 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Zinda Michael CENTRAL INDEX KEY: 0001815366 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39335 FILM NUMBER: 211473640 MAIL ADDRESS: STREET 1: C/O REPARE THERAPEUTICS INC. STREET 2: 7210 FREDERICK-BANTING, SUITE 100 CITY: ST-LAURENT STATE: A8 ZIP: H4S 2A1 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Repare Therapeutics Inc. CENTRAL INDEX KEY: 0001808158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: Z4 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7210 FREDERICK-BANTING, SUITE 100 CITY: ST-LAURENT STATE: A8 ZIP: H4S 2A1 BUSINESS PHONE: (857) 412-7018 MAIL ADDRESS: STREET 1: 7210 FREDERICK-BANTING, SUITE 100 CITY: ST-LAURENT STATE: A8 ZIP: H4S 2A1 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-11-23 0 0001808158 Repare Therapeutics Inc. RPTX 0001815366 Zinda Michael C/O REPARE THERAPEUTICS INC. 7210 FREDERICK-BANTING, SUITE 100 ST-LAURENT A8 H4S 2A1 QUEBEC, CANADA 0 1 0 0 EVP, Chief Science Officer Common Shares 2021-11-23 4 M 0 4122 1.637 A 4655 D Common Shares 2021-11-23 4 M 0 11856 1.637 A 16511 D Common Shares 2021-11-23 4 M 0 19590 2.062 A 36101 D Common Shares 2021-11-23 4 M 0 10473 2.425 A 46574 D Employee Stock Option (right to buy) 1.637 2021-11-23 4 M 0 4122 0.00 D 2027-06-14 Common Shares 4122 0 D Employee Stock Option (right to buy) 1.637 2021-11-23 4 M 0 11856 0.00 D 2027-12-04 Common Shares 11856 0 D Employee Stock Option (right to buy) 2.062 2021-11-23 4 M 0 19590 0.00 D 2029-03-29 Common Shares 19590 35260 D Employee Stock Option (right to buy) 2.425 2021-11-23 4 M 0 10473 0.00 D 2029-12-16 Common Shares 10473 137993 D Fully vested and exercisable. Twenty-five percent (25%) of the shares subject to the option vested on March 29, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested or shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date. Twenty-five percent (25%) of the shares subject to the option vested on December 16, 2020, and one thirty-ninth (1/39th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date. /s/ Steve Forte, Attorney-in-Fact 2021-12-06